Abstract 1037: Clinical application of next-generation digital PCR capable of real-time analysis to HER2 measurement as a novel diagnostic in breast cancer: A multicenter retrospective study
Authors: Hayeon Kim, Soo Young Park, Sohyeon Yang, Min Ji Song, Da Sol Kim, Jin hyuk Chang, YoonSik Kim, Hee-Joo Choi, Nam Hun Heo, Hee-Young Won, Ji-Hye Park, Minsik Song, Seung-Shick Shin, Do Young Lee, Si-Hyong Jang, Jeong-Yeon Lee, Han Suk Ryu
Journal: Cancer Research (2024)

Abstract HER2 testing is still challenging due to the subjective natures of immunohistochemistry (IHC) and in situ hybridization (ISH), standard methods for determining HER2 status. Here, we developed a clinically reliable HER2 testing method enabling ultra-fast detection of HER2 gene amplification with high accuracy by using the digital real-time PCR (drPCR) system. To test the clinical validity and standardize procedures of drPCR-based HER2 status evaluation, three independent breast cancer cohorts from different institutions were enrolled, which assigned as a training (SCHU hospital, n = 103) and two validation sets (SNU hospital, n = 170; CNUH hospital, n = 45), and the drPCR assay was compared with current standard HER2 testing methods. In the training cohort, the HER2/CEP17 ratio values from FISH and drPCR tests were highly correlated (r2 = 0.81; P &amp;lt; 0.001), and the drPCR results displayed 98.1% concordance to HER2 status defined by IHC and/or FISH with 92.6% sensitivity and 100% specificity. Eight samples further verified by targeted NGS showed 100% concordance of dPCR to NGS. Consistently, two validation cohorts also showed high concordance of drPCR to IHC and/or ISH results (accuracy = 97.1% and 97.8% in SNU and CNUH cohorts, respectively). The optimal cutoff for HER2 positivity in the drPCR assay was set as a HER2/CEP17 ratio ≥ 1.9 with AUC of 0.963 based on the results from training cohort, and the same cut-off for drPCR was applicable to two independent validation cohorts, supporting the clinical validity of our drPCR-based HER2 assessment. In some discordant cases, low tumor purity (≤ 25%) was observed and microdissection partly improved the drPCR results. The discordance between drPCR and ISH results was also found in marginal HER2+ cases with HER2/CEP17 ratio 2-3, but these cases showed inter-observer variability when re-evaluating the ISH/IHC data due to intratumoral HER2 heterogeneity. Of note, in HER2 IHC3+ cases with negative drPCR results, re-evaluation of IHC using an artificial intelligence (AI)-based HER2 scoring system revised the HER2 IHC 3+ score to 2+, and ISH assessment also confirmed that these cases are indeed HER2-negative, proving the high accuracy of HER2 CN drPCR assay. In conclusion, given the advantages of drPCR-based HER2 assessment with high accuracy, sensitivity, and simplicity, the drPCR assay could be a complementary or alternative method to IHC and ISH to greatly improve current HER2 testing. Citation Format: Hayeon Kim, Soo Young Park, Sohyeon Yang, Min Ji Song, Da Sol Kim, Jin hyuk Chang, YoonSik Kim, Hee-Joo Choi, Nam Hun Heo, Hee-Young Won, Ji-Hye Park, Minsik Song, Seung-Shick Shin, Do Young Lee, Si-Hyong Jang, Jeong-Yeon Lee, Han Suk Ryu. Clinical application of next-generation digital PCR capable of real-time analysis to HER2 measurement as a novel diagnostic in breast cancer: A multicenter retrospective study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1037.